This series on “Hepatocellular Carcinoma” is edited by Mehmet Akce, MD, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA; and Shishir K. Maithel, MD, FACS, Winship Cancer Institute, Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA.
In this special series, international experts provide an in-depth review of all the aforementioned topics. Despite nearly a decade of negative studies after approval of sorafenib, several new systemic therapy options have emerged in advanced HCC. The clinical trials which led to approval of several recently approved targeted therapy and immunotherapy agents are summarized. Potential systemic therapy options on the horizon and ongoing critical clinical trials are eloquently reviewed here.
Hepatocellular carcinoma: current state and future horizons
Epidemiology, mutational landscape and staging of hepatocellular carcinoma
Imaging diagnosis of hepatocellular carcinoma: LI-RADS
The optimal timing and management of hepatitis B and C in patients with hepatocellular carcinoma
Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver
Liver transplantation: expanding the donor and recipient pool
Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook
Liver-directed therapy for hepatocellular carcinoma
Efficacy and safety of radiotherapy for primary liver cancer
Systemic therapy for advanced hepatocellular carcinoma: targeted therapies
Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma
Hepatocellular carcinoma, novel therapies on the horizon
The series “Hepatocellular Carcinoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Shishir K. Maithel and Mehmet Akce served as the unpaid Guest Editors for the series.